Moreover, the CKD patients who received three doses of BNT162b2 showed significantly greater proportions of polyfunctional CD4+ T cells as well as an overall proportion of IFN-γ-producing T cells than patients who received heterologous schemes (Figure 3G). The gene discussed is CD4; the disease is chronic kidney disease.